rs619203 — ROS1 Ser2229Cys

Missense variant in the ROS1 receptor tyrosine kinase associated with atherothrombotic cardiovascular risk in some populations

See your personal result for ROS1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ROS1 Ser2229Cys — A Receptor Tyrosine Kinase Variant With Contested Cardiovascular Links

ROS1 encodes a receptor tyrosine kinase — a membrane-spanning signalling protein that responds to extracellular cues by triggering intracellular phosphorylation cascades that govern cell growth, differentiation, and survival. Unlike its better-known oncogenic role in non-small cell lung cancer11 non-small cell lung cancer
ROS1 gene fusions drive ~1–2% of NSCLC cases and are targeted by crizotinib, the germline missense variant rs619203 is a common population polymorphism affecting the kinase domain. The C allele substitutes cysteine for serine at position 2229 of the protein, a change that introduces a free thiol group in a region important for kinase regulation. This variant was first flagged in a 2005 multi-phase case-control study as one of four novel SNPs associated with myocardial infarction, but subsequent replication has been inconsistent across populations.

The Mechanism

ROS1 signals through receptor tyrosine kinase pathways22 receptor tyrosine kinase pathways
RTKs phosphorylate downstream targets including PI3K/AKT and RAS/MAPK cascades that regulate vascular smooth muscle proliferation, endothelial function, and inflammatory signalling. The Ser2229Cys substitution falls within the kinase domain of the protein. Serine at this position is a potential phosphorylation site, and its replacement by cysteine — which carries a reactive thiol side chain — could alter autophosphorylation dynamics, receptor activation threshold, or substrate specificity. Because ROS1 is expressed at low levels in cardiac and vascular tissue, the proposed mechanism is that subtle perturbations in RTK-mediated vascular signalling cumulatively influence atherothrombotic plaque vulnerability or endothelial inflammatory tone rather than causing a dramatic, easily measurable biochemical phenotype.

The Evidence

The association between rs619203 and cardiovascular risk originated with Shiffman et al. 200533 Shiffman et al. 2005
Shiffman D et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet. 2005;77(4):596-605, who conducted three sequential case-control studies totalling approximately 1,345 MI cases and 1,843 controls. They reported an OR of 1.75 for individuals homozygous for two risk alleles compared to non-carriers, with consistent directional effects across the three study phases. This was a significant initial signal in the era before large-scale GWAS.

Subsequent replication has been mixed. A Japanese association study of 3,432 individuals found the G→C polymorphism (Cys2229Ser) significantly associated with atherothrombotic cerebral infarction44 significantly associated with atherothrombotic cerebral infarction
Yamada Y et al. Genetic factors for ischemic and hemorrhagic stroke in Japanese individuals. Stroke. 2008;39(8):2211-8, extending the cardiovascular signal to stroke. A Siberian study of 200 MI patients and 420 controls also confirmed the association and noted a link between rs619203 genotype and fasting glucose levels, suggesting a metabolic component.

However, several European replication attempts have failed. A German study of 3,657 MI cases and 1,211 controls found no significant difference in allele frequencies between MI patients and controls55 no significant difference in allele frequencies between MI patients and controls
Koch W et al. Variations of specific non-candidate genes and risk of myocardial infarction. Int J Cardiol. 2011;148(3):339-44 (p≥0.25). A Russian cohort of young MI patients (<45 years) also found no significant association. These failures to replicate suggest either population-specific effects or that the initial signal reflected linkage to a causal variant not directly captured by rs619203. The overall evidence base qualifies this as emerging — insufficient for clinical use but biologically plausible.

Practical Actions

For CC homozygotes — who carry two copies of the Cys2229 allele and represent about 6% of people globally — monitoring of cardiovascular risk factors makes sense given the available signal, even without definitive clinical-grade evidence. The C allele frequency is highest in Europeans (~26%) and lowest in Africans (~8%), meaning the risk population is predominantly of European or East Asian ancestry. Standard cardiovascular biomarkers (hs-CRP, LDL, Lp(a)) and blood pressure tracking provide the most actionable handles for this genotype while the scientific evidence matures.

Interactions

rs619203 was initially identified alongside three other MI-associated SNPs in the same discovery study, including variants near rs499818. In the Siberian replication cohort, the strongest independent MI predictors were rs1333049 (9p21 locus) and rs10757278 (also 9p21), both of which showed more robust replication than rs619203. The 9p21 locus variants are well-established MI risk factors, and their co-presence with rs619203 in studies may represent confounding or additive — rather than synergistic — effects.

Genotype Interpretations

What each possible genotype means for this variant.

GG Serine Homozygote Normal

Common variant with no elevated cardiovascular risk from this SNP

You carry two copies of the G allele at rs619203, meaning your ROS1 protein has serine at position 2229 in both copies — the most common configuration globally. About 57% of people worldwide share this genotype. The available evidence does not assign elevated myocardial infarction or stroke risk to this genotype.

CG Cys2229 Carrier Intermediate

One copy of the Cys2229 allele — modest and uncertain cardiovascular signal

You carry one copy of each allele at rs619203: the G allele (Ser2229) and the C allele (Cys2229). About 36% of people globally share this genotype. The original 2005 discovery study reported a moderate dose-dependent increase in MI risk across carriers, and a Japanese study found an association with atherothrombotic stroke, but several European cohorts have not replicated these findings. The evidence is inconsistent — treat this as a weak signal to be considered alongside your overall cardiovascular risk profile.

CC Cys2229 Homozygote High Risk

Two copies of the Cys2229 allele — highest genotypic risk group for this SNP

The Cys2229 homozygote state introduces two free thiol groups at a position in the ROS1 kinase domain where serine normally resides. Whether this structurally perturbs kinase activity enough to measurably alter vascular signalling in vivo is not established by current functional data. The association signals that have emerged are strongest in Asian (Japanese, Siberian) populations and weakest or absent in German and Greek cohorts, raising the possibility that rs619203 may tag a causal variant in linkage disequilibrium that varies in its LD structure across ancestries. Until functional studies clarify the mechanism, this genotype warrants cardiovascular vigilance rather than alarm.